Your shopping cart is currently empty

Rac1-IN-5 is a selective, reversible inhibitor of the RAC1 protein with a dissociation constant (KD) of 30 nM. It competes specifically with guanine nucleotides for binding to RAC proteins, effectively blocking RAC1 activity and RAC1-dependent cellular functions. In vivo, Rac1-IN-5 exhibits anti-tumor metastasis effects and can improve survival rates. This compound is applicable for research on aggressive cancers such as triple-negative breast cancer and colon cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Rac1-IN-5 is a selective, reversible inhibitor of the RAC1 protein with a dissociation constant (KD) of 30 nM. It competes specifically with guanine nucleotides for binding to RAC proteins, effectively blocking RAC1 activity and RAC1-dependent cellular functions. In vivo, Rac1-IN-5 exhibits anti-tumor metastasis effects and can improve survival rates. This compound is applicable for research on aggressive cancers such as triple-negative breast cancer and colon cancer. |
| In vitro | Rac1-IN-5 (Compound A41) at 10 μM for 1 hour inhibits RAC1 activation and its dependent functions in EGF-stimulated NIH/3T3 fibroblasts. Additionally, Rac1-IN-5 at 10 μM decreases the activity of RAC P29S and RAC1b in NIH-3T3 fibroblasts expressing RAC wild-type (RAC1 WT) or RAC1 mutants (RAC1 P29S and RAC1b). In the concentration range of 0.01-10 μM, Rac1-IN-5 reduces RAC1-GTP levels, suppresses AKT hyperactivation, limits sphere migration areas, and inhibits colony formation in TNBC MDA-MB-468 luciferase (Luc) cells (IC 50 = 2.1 μM). Rac1-IN-5 also exhibits anti-invasive properties in human breast CAF spheroids at 10 μM. |
| In vivo | Rac1-IN-5 (Compound A41) administered at 25 mg/kg via intraperitoneal injection once daily for 4 weeks can prevent cancer cell metastasis in a mouse TNBC model. Additionally, Rac1-IN-5 at the same dosage and method of administration over 15 days can inhibit the metastasis of aggressive cancer in a CT26 cell xenograft BALB/c female mouse model. |
| Molecular Weight | 486.60 |
| Formula | C24H26N2O5S2 |
| Cas No. | 694515-65-6 |
| Smiles | O=C(NC1=CC=C(C=C1)S(=O)(=O)NC2=CC(OC)=CC=C2OC)CCSC3=CC=C(C=C3)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.